Abstract 937P
Background
Pain, fatigue and depression are commonly seen in cancer survivors and may co-occur. The extent of these symptoms occurring, alone or together, in head and neck cancer (HNC) is unknown. Using data from the Head and Neck 5000 cohort, we (i) investigated prevalence of the pain, fatigue, depression symptom cluster and (ii) explored its association with health-related quality of life (HRQoL).
Methods
Sociodemographic and clinical data were collected from participants at cohort recruitment (pre-treatment). At 12-months post-recruitment, cancer-related pain, fatigue and HRQoL were measured using the EORTC QLQ-C30, and depression using the Hospital Anxiety & Depression Scale (HADS). Cut-offs to define presence of clinically-important symptoms were: pain ≥25, fatigue ≥39 and depression ≥8. Associations between HRQoL score (on scale 1-100; higher score=better HRQoL) and the symptom cluster (0/1/2/3 symptoms), adjusted for clinical and sociodemographic variables, were assessed using multivariate linear regression.
Results
2,207 patients were included in the analysis. 47.3% had one or more symptoms of pain, fatigue or depression at clinically important levels. 20.3% had any one symptom, 13.7% had any two symptoms and 13.4% had all three symptoms. In the multivariate analysis, number of symptoms was strongly associated with HRQoL. After adjusting for other variables, presence of any one symptom was associated with a 13.4 point decrease (95% CI -15.2 to -11.7) in HRQoL, any two symptoms with a 26.3 point decrease (95% CI -28.3 to -24.3) and all three symptoms with a 42.3 point decrease (95% CI -44.3 to -40.2) in the HRQoL.
Conclusions
There is a high prevalence of the pain, fatigue and depression cluster in HNC survivors with over one in ten experiencing all three symptoms at 12-months. They have a significant negative impact on HRQoL. More attention should be given to identifying survivors experiencing this symptom cluster. Interventions targeted at addressing the cluster symptoms may help improve HRQoL amongst HNC survivors.
Clinical trial identification
N/A
Editorial acknowledgement
Funding
National Institute for Health and Care Research (NIHR).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1015P - The efficacy and mechanism of pan-FGFR inhibitor (AZD4547) combined with immunoagonists or immunosuppressants in FGFR-positive tumors
Presenter: Qizhi Ma
Session: Poster session 03
1016P - Phase I study of SOF10 plus atezolizumab in patients with advanced/recurrent solid tumours
Presenter: Toshihiko Doi
Session: Poster session 03
1017P - Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)
Presenter: Samuel Klempner
Session: Poster session 03
1018P - Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancer
Presenter: Omar Saavedra Santa Gadea
Session: Poster session 03
1019P - Bispecific PD1-IL2 antibody reshapes the inhibitory immune microenvironment of SMARCA4 mutant non-small cell lung cancer by reversing CD8+T cell exhaustion
Presenter: Bo Cheng
Session: Poster session 03
Resources:
Abstract
1020P - Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A*02:01
Presenter: Athanasia Dasargyri
Session: Poster session 03
1021P - Chemotherapy and hypomethylating agents enhance anti-tumor activity of PRAME ImmTAC
Presenter: Adel Benlahrech
Session: Poster session 03
1022P - A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Jonathan Riess
Session: Poster session 03
1023P - Long-term follow up of patients treated with a DNA vaccine (pTVG-HP) for PSA-recurrent prostate cancer
Presenter: Douglas McNeel
Session: Poster session 03
1024P - Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster session 03